Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

IsraCann Biosciences, Inc. Cannabis Stock

IsaCann Biosciences, Inc.

IsraCann Biosciences, Inc. (ISCNF) is Israel’s first pure-play cannabis company. They grow outside Tel Aviv and are trying to produce low cost cannabis for exportation into Europe. ISCNF cannabis stock is listed on the OTC markets and are headquartered in Vancouver, Canada.

Is ISCNF a strong BUY and HOLD?

IsraCann Biosciences Fundamental Analysis

Profile

HQ: Vancouver, BC, Canada
Founded: 2010
Facilities: Tel Aviv, Israel
Symbol: ISCNF (OTC), IPOT (CSE)

Focus: Strong

IsraCann is an Israeli firm focused on cultivation. They’re targeting outdoor grows to utilize the ground and sun in Israel to attempt to make low cost cannabis for export into Europe.

They are targeting production costs of only $0.40 per gram (compared to an average of $1.50 per gram in Canada). 

Size: Weak

Market Cap: US $24.27 mil
Enterprise Value: US $21.75 mil
# of employees: 3

Markets: Strong

Primary: Israel
Secondary: Europe starting with Germany
Majority Subsidiaries:   Cannisra crops Ltd, Isracann Holdings Inc, The Cranium
 

Operations: Neutral

Cultivation:
Current production: They have a JV  with 55,000 sq ft
Future capacity:  The JV can grow to 160,000 sq ft in greenhouses with lots of outdoor land available to them. Their own facility will be 230,000 sq ft and have capacity of 23,500 kg per year.

Israel was the 3rd country to develop an export framework for cannabis (behind Canada and the Netherlands). They will use this to their advantage and supply Europe with their low cost cannabis.

Israel has 46,000 medical patients with 90,000 anticipated by year’s end. 

Distribution:
Direct sales: Yes
Store networks: None

Integration/Diversification: 
Vertically integrated: Yes
Horizontally diversified: No

Financials: Weak

2020 Revenue (ttm): $310,346
Outstanding shares (diluted): 135 mil
Return on Equity: -116%

Management: Weak

President, CEO, Director: Darryl Jones
CFO: Yana Popova
COO: Matt Chatterton

Management experience includes investment advising, project management, and accounting.

Branding: Neutral

They will rely heavily on the “made in Israel” brand with a focus on quality. Both cannabis for export as well as CBD products will be explored. Low cost, lots of sun, and good soil are all benefits of growing in Israel.

Valuation: Neutral

Current share price: US $0.1748
Price to Sales: 8.83 (Tobacco industry = 5)
52 week low/high: US $0.0908- $0.549
EV/Revenue: 54.02
Price/book: 1.21

Financing: Weak

After Q3 2020 (August 31st, 2020) they had $3 million of working capital. They raised about $150k through warrants and options. The company has around $1 million in debt.

ISCNF Technical Analysis

Should I buy IsraCann Biosciences?

Follow Stephen Goldman as he evaluates IsraCann Biosciences (ISCNF) using different moving averages, the Aroon Up/Down, and the stochastic RSI.

Remember sound cannabis stock trading strategies include both Fundamental Analysis and Technical Analysis.

/
Day Range -
52 Week Range -
Market Cap
Shares Traded
Volume

Bottom Line: Is IsraCann Biosciences Cannabis Stock a Buy?

Recommendation: Neutral (for now)

IsraCann Biosciences, Inc. is a cannabis cultivator in Israel. They are striving to become a low cost cultivator, which will give them an advantage in exporting their products to Germany and eventually all of the EU.

IsraCann has been slightly delayed in planting their first crop and blame covid-19 as well as licensing. The good news is that the Israeli government has approved rules for export of cannabis. This export will occur at a fixed price of CAD $5.50 per gram. If they are indeed able to produce cannabis at $0.40 per gram there would be fantastic profit margins in supplying the EU with smokable cannabis.

Locally the Israeli market is growing too. With an estimated 200,000 patients consuming an estimated 85 tonnes per year, there should be plenty of demand locally. Although they have no revenue yet from cannabis related businesses, they do have promise. They just need to get that first crop planted.

The company reported losses of $838,792 during the three months ending August 31st, 2020. This is compared to new losses of $894,848 in 2019. They have around $3 million in working capital so they can fund most of 2021 now. Without significant revenue after that from cultivating they will need to raise funds.

We generally like this company, although the management team is slightly inexperienced. If they can have a few successful harvests and export to Germany, there will be revenue to drive stock prices higher. This is at least 5-6 months away however. For the short term, this is rated Neutral but watch it long term for this to switch to Strong.

If you are looking for more productive cannabis companies, check out our Featured Companies Page for many other winners in the cannabis and hemp industry.

Symbol Name Last Price Change % Change
Algorithmic Stock Trading Hemp Stocks

2 Cannabis Stocks Set to Double in 2021

2 Cannabis Stocks Set to Double in 2021 The cannabis industry has gained plenty of momentum over the last couple of months. Folks in 36 states now have access to medical cannabis and federal decriminalization seems more imminent now than ever. It may be time for...

What are the Top 3 Cannabis Beverage Stocks for 2021?

What are the Top 3 Cannabis Beverage Stocks for 2021? The CBD infused beverages market is exploding. In fact, this emerging market will have a value of nearly $3 Billion in the next 4 years. Many cannabis and hemp companies are cashing in on the opportunity, allowing...

Should You Buy Curleaf Stock Before the Q4 Earnings Call?

Should You Buy Curleaf Stock Before the Q4 Earnings Call? Cannabis legalization in various US states are proving to be an absolute game-changer in the market. Multiple cannabis stocks have gained momentum, and a few companies surprised investors with their expansion...

Sundial Growers: Should You Buy this Cannabis Stock?

Sundial Growers: Should You Buy this Cannabis Stock? Canada is one of the largest hubs for the cannabis industry. It has also become one of the largest producers of cannabidiol (CBD), and other cannabis-based medications. As with any emerging industry, we tend to see...

Top 3 Cannabis ETFs to Watch in 2021

Top 3 Cannabis ETFs to Watch in 2021 Legal cannabis has been slowly growing in the United States since the campaign to legalize marijuana for medical and recreational purposes. In 2018, the cannabis industry was valued at $12 billion US dollars. It is now expected to...

Trulieve: Top Cannabis Stock for 2021

Trulieve: Top Cannabis Stock for 2021 The global cannabis industry is set to quadruple in the next six years from a $20 billion industry to a $90 billion one. Post Biden’s win, the industry has found a new reason to cheer.  The new administration's pro-pot stance will...